Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096304 · ClinicalTrials.gov registry record · Phase 1
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00096304 is a Phase 1 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 36 participants.
The verdict
NCT00096304, a Phase 1 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.
Interventions
- DRUG docetaxel
- DRUG epirubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-06-08 |
| Est. Completion | 2007-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096304
The ClinicalTrials.gov registry entry for NCT00096304 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00096304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096304 about?
NCT00096304 is a clinical study titled "Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin...
What is the current status of trial NCT00096304?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-06-08. Estimated completion is 2007-11-30.
What interventions are being tested in trial NCT00096304?
The interventions under investigation include: docetaxel (DRUG), epirubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00096304?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.